such as balsam of Peru, cinnamates and lanolin, or some pigments. [1] Considering that patch testing is not a very useful method to differentiate these two conditions, detailed history, morphology and color of the lesions, and histopathologic demonstration of classical findings of LPP confirm the diagnosis.
Treatment modalities for LPP include topical application of mild or potent steroids, tacrolimus, oral administration of dapsone, retinoic acid derivatives, cyclosporine, and phototherapy. [3] For cases of LPP of eyelids, tacrolimus should be used for topical application to avoid ocular side effects of topical steroids.
Description of such a unique case further expands the dimension of clinical variants of LPP, warranting its consideration as an important differential diagnosis in all doubtful cases.
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Sir, Vitiligo is a common dermatologic disease with a debated etiology. Infectious agents have been claimed to trigger disease development through antibody production, molecular mimicry, cytokine production, major histocompatibility complex activation, regulatory T-cell dysfunction, immune complex formation, and chronic inflammatory damage. [1] Helicobacter pylori (H. pylori) is one of the most common pathogens affecting humans, infecting approximately 50% of the world's population. [2] The prevalence of infection varies in different governorates in Egypt. Reported prevalence in Delta is approximately 70%.
[3] Several immune-mediated skin disorders have been considered to have a relationship with H. pylori infection.
The aim of the present study was to evaluate if there is a relationship between active vitiligo and H. pylori infection.
Seventy-five patients with non segmental vitiligo were selected [51 (68%) cases with active disease and 24 (32%) with stable disease]. Seventy-five healthy, age and gender-matched subjects were enrolled as a control group. A written consent form approved by local Ethical Research Committee was obtained from every participant prior to study initiation.
The diagnosis of vitiligo was made on the basis of typical clinical features and Wood's light examination. All studied cases were either newly diagnosed or old patients with completely depigmented lesions. Assessment of disease activity was done according to the Vitiligo Disease Activity (VIDA) score. [4] Clinical data of selected cases and controls are summarized in Table 1 .
Patients with dermatological diseases other than vitiligo, with autoimmune diseases or malignancy, those who took previous H. Pylori eradication treatment, and those using NSAIDs, antibiotics, or proton pump inhibitors in the last month before the study were excluded.
Diagnosis of infection was done by stool antigen test (SAT)
which is a noninvasive method with good sensitivity and specificity, in global meta-analysis, in the diagnosis of H. Pylori infection. [5] Measurement of serum IgG antibody was done to avoid the influence of different factors on SAT positivity. [6] H. pylori specific IgG antibody in serum and SAT were detected by enzyme-linked immunosorbent assay (ELISA). As the presence of antibody may denote active or past infection, included cases with both positive SAT and IgG were designated as having active infection.
For SAT, level <20 ng/ml denotes negative result and level >20 ng/ml denotes positive result. [7] For H. pylori IgG in serum, level <20 u/ml denotes negative result and level >20 u/ml denotes positive result. [8] Data were collected, tabulated, and statistically analyzed using a personal computer with SPSS version 11 software (SPSS Inc, Chicago, Illinois, USA). Fisher's exact test was used for comparison of qualitative variables in 2 × 2 tables when expected cell count of more than 25% of cases was less than 5. Chi-square test (χ 2 ) was used to study the association between two qualitative normally distributed variables. Mann-Whitney U test was used for comparison between two groups not normally distributed having quantitative variables. Differences were considered statistically significant with P < 0.05.
H. pylori infection was positive in 49 (65.3%) vitiligo cases compared with 18 (24%) in the control group (P = 0.001) [ Figure 1 ]. In cases, infection was significantly associated with high VIDA score (P = 0.009) and with active disease (P = 0.02) [ Table 2 ].
H. pylori may alter cellular immunity resulting in loss of self-tolerance and autoimmune destruction of melanocytes. This autoimmune reaction results from higher levels of C-reactive protein, chronic inflammatory condition, autoantibody production, and antigenic stimulation. [9] In addition, local inflammation of gastric mucosa leads to release of inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, and IL-1β] that produce systemic inflammation which subsequently affect skin microenvironment with loss of functional melanocytes. [10] The current study demonstrated significant association between active vitiligo and H. pylori infection. On the contrary, Dogan et al. reported absence of association between H. pylori positivity and vitiligo activity score. [11] Çakmak et al. showed no significant relationship between H. Pylori SAT positivity and activity of vitiligo. [12] In the current work, positive cases for H. Pylori infection received eradication therapy consisting of omeprazole 20 mg BID, clarithromycin 500 mg BID, and metronidazole 500 mg BID for 14 days. [13] Follow-up 3 months later showed suppression of disease activity in (11/49) cases.
Non responding cases regarding disease activity may be explained by the multifactorial etiology of vitiligo. 
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